- Published
- 22 July 2021
- Journal article
Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021
- Authors
-
- Source
- Eurosurveillance
Abstract
The I-MOVE-COVID-19 primary care/outpatient study sites are: England, France, Ireland, the Netherlands, Portugal, Scotland, Spain (three regions), Spain (Navarra region) and Sweden (Table 1). Study sites adapted the I-MOVE-COVID-19 VE study protocol [2], to their country-specific setting. Sites included all, or a systematic sample of, acute respiratory infection (ARI) patients or patients presenting with common COVID-19 symptoms (at least one of the following symptoms: fever, cough, shortness of breath, sudden onset of anosmia/ageusia) who contacted the sentinel physician (Table 1). The Navarra region included all patients presenting to the health service primary care physicians. A systematic sample of patients in COVID-19 testing centres both with and without physician referral were included in Portugal. Scotland included a systematic sample of patients presenting to community-based COVID-19 centres with self- and clinical staff-based swabbing.
Rights
This work is licensed under a Creative Commons Attribution 4.0 International License. http://creativecommons.org/licenses/by/4.0/
Cite as
Kissling, E., Hooiveld, M., Martin, V., Martínez-Baz, I., William, N., Vilcu, A., Mazagatos, C., de Lusignan, S., Meijer, A., Machando, A., Brytting, M., Casado, I., Murray, J., Behillil, S., Larrauri, A., O'Donnell, J., Tsang, R., de Lange, M., Rodrigues, A., Riess, M., Castilla, J., Hamilton, M., Falchi, A., Pozo, F., Dunford, L., Cogdale, J., Jansen, T., Guiomar, R., Enkirch, T., Burgui, C., Sigerson, D., Blanchon, T., Ochoa, E., Connell, J., Ellis, J., van Gageldonk-Lafeber, R., Kislaya, I., Rose, A., Valenciano, M. & team, I. 2021, 'Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021', Eurosurveillance, 26(29). https://doi.org/10.2807/1560-7917.ES.2021.26.29.2100670